Navigation Links
New drug for non-Hodgkin lymphoma and chronic lymphocytic leukemia passes early test
Date:5/23/2014

A new chemotherapy drug being investigated for its potency against two types of cancer was found by scientists at Houston Methodist and seven other institutions to be effective in about one-third of the 58 patients who participated in a phase I study.

The drug, alisertib or MLN8237, inhibits the enzyme aurora A kinase, which is known to be very active during cell division. The present study, published in the journal Investigational New Drugs, looks at the safety, tolerability, and preliminary success of alisertib in treating non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

"An advantage with this drug is it is oral and very effective in a significant number of patients with aggressive lymphoma when used at that dose for 7 days out a 21 day cycle," said hematologist Swaminathan Iyer, M.D., who led the multi-site study.

Drugs commonly used to treat NHL and CLL are chemotherapeutic drugs and some biological targeted agents such as the monoclonal antibodies rituximab, ofatumumab and obinutuzumab with varying degrees of success.

Although about 1/2 of patients participating in the phase I study experienced side effects most of which were manageable events, Iyer said that is not unusual for such biologic (non chemotherapy) drugs.

"The side effects were fairly tolerable in this study," Iyer said. "We would like to see more information from a larger group of patients to fully understand the drug's safety and tolerability for those experiencing the middle-to-later stages of these diseases."

Iyer and his group recommend 50 mg, twice-daily doses of alisertib for the advanced phase trials of the drug, which Iyer says has begun enrollment.

Alisertib is not yet approved for general medical use by the FDA. Its impact on T cell lymphoma is being investigated in a separate, phase III trial for a specific type of lymphoma called the T cell lymphomas. Houston Methodist is a participating study site for that project. Initial phase II reports in these T cell lymphomas showed a 57% response, the highest ever noted for any single agent in this disease entity.


'/>"/>

Contact: David Bricker
dmbricker@houstonmethodist.org
832-667-5811
Houston Methodist
Source:Eurekalert

Related medicine news :

1. Epigenomic abnormalities predict patient survival in non-Hodgkins lymphoma
2. Novel drug therapy targets aggressive form of non-Hodgkins lymphoma
3. International symposium will address non-Hodgkins lymphoma in the young
4. Inhibition of CDK4 might promote lymphoma development and progression
5. Increased risk of relapse omitting RT in early PET scan negative Hodgkin lymphoma
6. Chemo-free treatment a possibility for leukemia/lymphoma
7. Scientists explore promising new option for first line of attack in lymphoma
8. Breakthrough in treating leukemia, lymphoma with umbilical cord blood stem cells
9. MedMar Healing Center Co-founder Rafael Hernandez Goes the Distance for Leukemia and Lymphoma Society, Running Three Marathons for Nonprofit Health Organization
10. Research shows genetic anti-inflammatory defect predisposes children to lymphoma
11. Reprogrammed treatment-resistant lymphomas respond to cancer drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... Mediaplanet today announces the ... healthy lifestyles and highlighting the importance of proactive eye and ear health. The ... the latest innovations in hearing aid technology. , In this issue, the ...
(Date:8/18/2017)... ... 18, 2017 , ... Mediaplanet today announces the launch of ... and highlighting the importance of proactive eye and ear health. The campaign focuses ... innovations in hearing aid technology. , In this issue, the American Speech-Language-Hearing ...
(Date:8/18/2017)... ... 18, 2017 , ... The Dawn Johnson Insurance Group, a Missouri-based insurance and ... generate community support for efforts to educate the local population on cancer realities while ... of cancer. , Each day in America, roughly 4,600 new cases of cancer ...
(Date:8/18/2017)... ... 2017 , ... Radabaugh & Associates, a family managed agency ... West Virginia, is embarking on a cooperative charity effort with the Chestnut Mountain ... Chestnut Mountain Ranch (CMR) is a Christ-centered boarding school for young men offering ...
(Date:8/18/2017)... Plantation, FL (PRWEB) , ... August 18, 2017 ... ... asset protection and financial planning assistance that serves communities throughout southern Florida, is ... event to provide scholarship assets to children from low income families. , The ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... Aug. 7, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Saban as president, effective Aug. 7, 2017. ... decided to pursue other interests and will serve as president ... Paul has served us in multiple leadership roles since he ... Jun. 2015 and has provided decisive, strategic leadership which continues ...
(Date:8/7/2017)... 2017  Endo International plc (NASDAQ: ENDP ... virtually all known U.S. mesh product liability claims and ... known remaining U.S. claims at reasonable values. Under the ... fourth quarter of 2017 and continuing through the fourth ... 2017 results, the Company intends to increase its mesh ...
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131.  This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...
Breaking Medicine Technology: